← Leaderboards
David S Perlin
Hackensack University Medical Center
$64,528,944
Attributed
$64,528,944
Total exposure
21
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $93.5M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$205,063,508 · 26
By mechanism
U19$172,019,887 · 17
R01$24,873,493 · 5
U54$3,779,446 · 1
U01$3,468,675 · 1
R21$922,007 · 2
Top collaborators
- Arturo Casadevall1 shared
- Charles M. Rice1 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPharmaceutical PreparationsDrug ResistanceResistanceIn VivoProgramsPathogenLeadIn VitroMulti-Drug ResistanceMorbidity - Disease RateDrug DevelopmentMutationInnovationReportingBaseCellsMolecularPre-ClinicalDesignRodentPropertyCollaborationsCandida
Grant awards (95)
Center for accelerated development of drug candidates targeting high threat bacterial infections$7,562,521
U19 · FY2025 · AI · contact PI
Accelerator for the rapid development of countermeasures targeting drug resistant fungal pathogens$6,977,446
U19 · FY2025 · AI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$2,558,055
R01 · FY2025 · AI · contact PI
A novel 'fungerp' targeting refractory Candida urinary tract infections$899,250
U19 · FY2025 · AI · contact PI
Advanced development of a potent dual-targeting TriBE class lead candidate to treat highly drug resistant Neisseria gonorrhoeae$534,504
U19 · FY2025 · AI · contact PI
Center for accelerated development of drug candidates targeting high threat bacterial infections$273,779
U19 · FY2025 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$837,746
R01 · FY2024 · AI · contact PI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents$6,521,325
U19 · FY2023 · AI · contact PI
Core E Animal Infection Models$1,449,552
U19 · FY2023 · AI · contact PI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens$1,142,038
R01 · FY2023 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$857,021
R01 · FY2023 · AI · contact PI
Administrative Core$734,932
U19 · FY2023 · AI · contact PI
Metropolitan AntiViral Drug Accelerator$65,141,731
U19 · FY2022 · AI · contact PI
Administrative Core$7,558,755
U19 · FY2022 · AI · contact PI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents$6,638,250
U19 · FY2022 · AI · contact PI
Animal Model Core$5,580,377
U19 · FY2022 · AI · contact PI
Accelerated development of advanced leads against SARS-CoV-2 and other pandemic viruses$3,885,770
U19 · FY2022 · AI · contact PI
Core E Animal Infection Models$1,181,034
U19 · FY2022 · AI · contact PI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens$1,142,038
R01 · FY2022 · AI · contact PI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections$1,076,832
R01 · FY2022 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata$710,571
R01 · FY2022 · AI · contact PI
Administrative Core$543,300
U19 · FY2022 · AI · contact PI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents$6,639,071
U19 · FY2021 · AI · contact PI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens$1,125,966
R01 · FY2021 · AI · contact PI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections$1,076,832
R01 · FY2021 · AI · contact PI
Core E Animal Infection Models$852,328
U19 · FY2021 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata$710,571
R01 · FY2021 · AI · contact PI
Administrative Core$522,176
U19 · FY2021 · AI · contact PI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents$6,638,108
U19 · FY2020 · AI · contact PI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens$1,136,490
R01 · FY2020 · AI · contact PI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections$1,051,346
R01 · FY2020 · AI · contact PI
Core E Animal Infection Models$866,758
U19 · FY2020 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$710,571
R01 · FY2020 · AI · contact PI
A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs$619,850
U19 · FY2020 · AI · contact PI
Administrative Core$560,955
U19 · FY2020 · AI · contact PI
Center to develop innovative therapeutics to multidrug resistant high-threat bacterial agents$6,880,060
U19 · FY2019 · AI · contact PI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens$1,362,765
R01 · FY2019 · AI · contact PI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections$1,070,621
R01 · FY2019 · AI · contact PI
Core E Animal Infection Models$941,758
U19 · FY2019 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata$710,571
R01 · FY2019 · AI · contact PI
Administrative Core$353,165
U19 · FY2019 · AI · contact PI
Center to develop therapeutic countermeasures to high-threat bacterial agents$3,306,934
U19 · FY2018 · AI · contact PI
Center to develop therapeutic countermeasures to high-threat bacterial agents$1,947,337
U19 · FY2018 · AI · contact PI
Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections$1,244,665
R01 · FY2018 · AI · contact PI
Animal Model Core$443,483
U19 · FY2018 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candidaglabrata$380,639
R01 · FY2018 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$296,212
R01 · FY2018 · AI · contact PI
Animal Model Core$240,759
U19 · FY2018 · AI · contact PI
Administrative Core$162,473
U19 · FY2018 · AI · contact PI
Administrative Core$52,912
U19 · FY2018 · AI · contact PI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,504,272
U19 · FY2017 · AI · contact PI
Animal Model Core$698,460
U19 · FY2017 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$524,999
R01 · FY2017 · AI · contact PI
Administrative Core$255,368
U19 · FY2017 · AI · contact PI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,504,272
U19 · FY2016 · AI · contact PI
Animal Model Core$653,683
U19 · FY2016 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$524,999
R01 · FY2016 · AI · contact PI
Administrative Core$469,677
U19 · FY2016 · AI · contact PI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,254,272
U19 · FY2015 · AI · contact PI
Animal Model Core$624,528
U19 · FY2015 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$524,999
R01 · FY2015 · AI · contact PI
Administrative Core$224,809
U19 · FY2015 · AI · contact PI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,399,115
U19 · FY2014 · AI · contact PI
Animal Model Core$698,474
U19 · FY2014 · AI · contact PI
Critical Factors Influencing Echinocandin Resistance in Candida glabrata$487,650
R01 · FY2014 · AI · contact PI
Administrative Core$222,304
U19 · FY2014 · AI · contact PI
Linking Triazole Resistance and Fitness in Aspergillus fumigatus$198,750
R21 · FY2014 · AI · contact PI
Animal Core$676,682
U54 · FY2013 · AI · contact PI
Linking Triazole Resistance and Fitness in Aspergillus fumigatus$195,451
R21 · FY2013 · AI · contact PI
Linking Triazole Resistance and Fitness in Aspergillus fumigatus$43,006
R21 · FY2013 · AI · contact PI
Animal Core$676,051
U54 · FY2012 · AI · contact PI
Animal Core$807,693
U54 · FY2011 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$420,716
R01 · FY2011 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$16,759
R01 · FY2011 · AI · contact PI
Animal Core$871,476
U54 · FY2010 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$378,765
R01 · FY2010 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$61,428
R01 · FY2010 · AI · contact PI
Animal Core$747,544
U54 · FY2009 · AI · contact PI
A Rapid and Expandable Nucleic Acid Platform to Detect Bloodstream Infections$723,595
U01 · FY2009 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$382,590
R01 · FY2009 · AI · contact PI
A Rapid and Expandable Nucleic Acid Platform to Detect Bloodstream Infections$335,767
U01 · FY2009 · AI · contact PI
Rapid and Expandable Nucleic Acid Platform to Detect Bloodstream Infections$757,554
U01 · FY2008 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$382,590
R01 · FY2008 · AI · contact PI
Rapid and Expandable Nucleic Acid Platform to Detect Bloodstream Infections$638,889
U01 · FY2007 · AI · contact PI
Mechanism of clinical resistance to echinocandin antifungal drugs$350,906
R01 · FY2007 · AI · contact PI
A Rapid and Expandable Nucleic Acid Platform to Detect *$392,413
U01 · FY2006 · AI · contact PI
A Rapid and Expandable Nucleic Acid Platform to Detect *$181,054
U01 · FY2006 · AI · contact PI
Rapid and Expandable Nucleic Acid Platform to Detect *$439,403
U01 · FY2005 · AI
ENERGY COUPLING BY THE YEAST PLASMA MEMBRANE H+_ATPASE$421,762
R01 · FY2004 · GM
Rapid Evaluation of Drug Resistance in Pathogenic Fungi$233,400
R21 · FY2004 · AI
ENERGY COUPLING BY THE YEAST PLASMA MEMBRANE H+_ATPASE$409,611
R01 · FY2003 · GM
Rapid Evaluation of Drug Resistance in Pathogenic Fungi$233,400
R21 · FY2003 · AI
Rapid Evaluation of Drug Resistance in Pathogenic Fungi$18,000
R21 · FY2003 · AI
ENERGY COUPLING BY THE YEAST PLASMA MEMBRANE H+_ATPASE$397,813
R01 · FY2002 · GM
ENERGY COUPLING BY THE YEAST PLASMA MEMBRANE H+_ATPASE$386,356
R01 · FY2001 · GM